THEMIS MEDICARE
|
|
BOM : 530199     NSE : THEMISMED     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Average |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Oct 10,2024 |
Price(EOD): ₹ 272.60
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 2,507.92 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
THEMIS MEDICARE | 0.4% | 9.1% | 42.8% |
SUN PHARMACEUTICAL INDUSTRIES | -1.2% | 2.8% | 71.4% |
CIPLA | -0.3% | -0.8% | 44.6% |
DR REDDYS LABORATORIES | -0.8% | -1% | 23% |
ZYDUS LIFESCIENCES | -0% | -5% | 76.5% |
DIVIS LABORATORIES | 9.6% | 9.4% | 60.9% |
FUNDAMENTAL ANALYSIS OF THEMIS MEDICARE
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF THEMIS MEDICARE
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
81.27
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 30.87 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 6.64
P/B Calculated based on Book Value of Rs 377.67 Cr
[Latest Year - Mar2024 - Consolidated Results ] 6.15
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 408.11 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
251% 276% 359% |
SHARE PRICE MOMENTUM OF THEMIS MEDICARE
THEMIS MEDICARE vs SENSEX
DEBT OF THEMIS MEDICARE
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.32 0.33 0.32 0.32 |
0.25 0.27 0.27 0.26 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF THEMIS MEDICARE
Pledged Promoter Shares |
2.43 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF THEMIS MEDICARE
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
25.74% 213.86% 389.94% 508.98% |
27.26% 34.2% 50.33% 49.04% |
QtrlyTrend |
8 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
THEMIS MEDICARE related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 0.7% | 1.6% | 57.8% |
S&P BSE SMALL CAP | -0.1% | 1.3% | 49.7% |
S&P BSE MIDSMALLCAP | -0.2% | 0.6% | 50.5% |
S&P BSE ALLCAP | -0.6% | 0.3% | 37.5% |
You may also like the below Video Courses
FAQ about THEMIS MEDICARE
Is THEMIS MEDICARE good for long term investment?
As on Oct 10,2024, the Fundamentals of THEMIS MEDICARE look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of THEMIS MEDICARE . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is THEMIS MEDICARE UnderValued or OverValued?
As on Oct 10,2024, THEMIS MEDICARE is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of THEMIS MEDICARE ?
As on Oct 10,2024, the Intrinsic Value of THEMIS MEDICARE is Rs. 72.44 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 77.66
Fair Value [Median EV / Sales Model] : Rs. 72.44
Fair Value [Median Price / Sales Model] : Rs. 59.34
Estimated Median Fair Value of THEMIS MEDICARE : Rs. 72.44
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.